Authorities arrested a 70-year-old Carrollton man last week after uncovering an illegal opioid distribution operation from ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

While New Orleans prepares for the excitement of the big game, it’s important to remember that sports injuries aren’t limited to the professionals. High school athletes, weekend warriors, and generall ...

The amount of women who were diagnosed with a substance use disorder in Ohio when they delivered their babies has increased over the years, but are the resources in our communities available to help ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

More New Yorkers received scripts for buprenorphine, a med used to treat opioid addiction, amid fight against record-high ...

School district employees who administer the emergency antagonists in compliance with state law are immune from civil liability. CDC data points out that while overall fentanyl overdoses in the U.S.

Adolore BioTherapeutics (”Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the ...

Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of therapy.

Distribution of prescribed opioid analgesics is lower in majority non-White versus majority White communities across all levels of socioeconomic deprivation.